Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
SLAS Discov ; 29(1): 66-76, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37925159

RESUMEN

A rapid drug discovery response to influenza outbreaks with the potential to reach pandemic status could help minimize the virus's impact by reducing the time to identify anti-influenza drugs. Although several anti-influenza strategies have been considered in the search for new drugs, only a few therapeutic agents are approved for clinical use. The cytopathic effect induced by the influenza virus in Madin Darby canine kidney (MDCK) cells has been widely used for high-throughput anti-influenza drug screening, but the fact that the MDCK cells are not human cells constitutes a disadvantage when searching for new therapeutic agents for human use. We have developed a highly sensitive cell-based imaging assay for the identification of inhibitors of influenza A and B virus that is high-throughput compatible using the A549 human cell line. The assay has also been optimized for the assessment of the neutralizing effect of anti-influenza antibodies in the absence of trypsin, which allows testing of purified antibodies and serum samples. This assay platform can be applied to full high-throughput screening campaigns or later stages requiring quantitative potency determinations for structure-activity relationships.


Asunto(s)
Gripe Humana , Animales , Perros , Humanos , Gripe Humana/tratamiento farmacológico , Ensayos Analíticos de Alto Rendimiento , Línea Celular , Células de Riñón Canino Madin Darby , Técnica del Anticuerpo Fluorescente
2.
SLAS Discov ; 29(5): 100160, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38761981

RESUMEN

Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.


Asunto(s)
COVID-19 , Ensayos Analíticos de Alto Rendimiento , Pandemias , SARS-CoV-2 , Humanos , COVID-19/epidemiología , COVID-19/virología , SARS-CoV-2/efectos de los fármacos , Ensayos Analíticos de Alto Rendimiento/métodos , Antivirales/uso terapéutico , Antivirales/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA